← All organizations
Highest phase reached
Phase 4
First clinical trial
Jan 1, 1999First marketed drug
Apr 20, 2000First NDA
Apr 20, 2000Last known activity
Jan 1, 2017
Acquired by Sanofi-Synthelabo → Sanofi-Aventis on Jan 1, 2004
Timeline
1990s
- Jan 1, 1999
Aventis— Founded
- Jan 1, 1999
Hoechst Marion Roussel— Acquired
- Jan 1, 1999
Rhone-Poulenc Rorer— Acquired
2000s
- Jan 1, 2004
Sanofi-Synthelabo— Acquired By
- Jan 1, 2004
Sanofi-Aventis— Now
- Apr 16, 2004
insulin glulisine— NDA Organization
Drugs by trial phase (83 distinct, 104 trials)
Phase 4 (3 own, 2 via acquisition)
Phase 3 (16 own, 3 via acquisition)
Phase 2 (22 own, 8 via acquisition)
Phase 1 (5 own, 4 via acquisition)
Other trials (2 own, 18 via acquisition)
Indications
Approved for
Studied for
- Adenocarcinoma
- Atrophy
- Bacterial Infections
- Brain Injuries
- Brain Injuries, Traumatic
- Breast Neoplasms
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Squamous Cell
- Cardiovascular Diseases
- Colorectal Neoplasms
- Communicable Diseases
- Coronary Artery Disease
- Coronary Disease
- Diabetes Mellitus, Type 2
- Digestive System Neoplasms
- Disease Progression
- Ehlers-Danlos Syndrome
- Esophageal Neoplasms
- Gastrointestinal Neoplasms
- Glucose Intolerance
- Glucose Metabolism Disorders
- Gram-Positive Bacterial Infections
- Head and Neck Neoplasms
- HIV Infections
- Hypertension
- Infections
- Inflammatory Breast Neoplasms
- Kidney Diseases
- Kidney Failure, Chronic
- Lung Neoplasms
- Melanoma
- Metabolic Diseases
- Multiple System Atrophy
- Myocardial Ischemia
- Neoplasms, Squamous Cell
- Otitis
- Otitis Media
- Otitis Media with Effusion
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Peritoneal Neoplasms
- Pleural Effusion
- Prostatic Neoplasms
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Rhinitis
- Sarcoma
- Shy-Drager Syndrome
- Small Cell Lung Carcinoma
- Squamous Cell Carcinoma of Head and Neck
- Stomach Neoplasms
- Supranuclear Palsy, Progressive
- Syndrome
- Thrombosis
- Uterine Cervical Neoplasms
- Venous Thrombosis
- Wounds and Injuries
Marketed drugs (4)
Subsidiaries (2 direct, 24 total across the full acquisition tree)
- Hoechst Marion Roussel
- Rhone-Poulenc Rorer
- Applied Immunesciences L2
- Fisons L2
- Hoechst L2
- Marion Merrell Dow L2
- Rhone Poulenc L2
- Rorer L2
- Connaught Laboratories L3
- Lloyd Brothers Pharmacists Inc L3
- Marion Laboratories L3
- Merrell Dow L3
- Pasteur Merieux L3
- Poulenc Freres L3
- Revlon L3
- Roussel-Uclaf L3
- Society of Rhone Chemical Factories L3
- Theraplix L3
- Greyhound Corp L4
- Hed Pharmaceuticals L4
- Laboratorios Grossman SA L4
- Merieux Institute L4
- Nysco Laboratories L4
- US Vitamin and Pharmaceutical Corporation L4
Recent trials (50)
- NCT03004001CollaboratorN/AJan 1, 2017
- NCT00426127CollaboratorPhase 2Nov 1, 2006
- NCT00288444CollaboratorPhase 1Jan 1, 2006
- NCT00270894CollaboratorPhase 2Nov 1, 2005
- NCT00279916CollaboratorPhase 3Sep 1, 2005
- NCT00232479CollaboratorPhase 2Sep 1, 2005
- NCT00268593CollaboratorPhase 2Aug 1, 2005
- NCT00216008CollaboratorPhase 2Jul 1, 2005
- NCT00193180CollaboratorPhase 2May 1, 2005
- NCT00118053CollaboratorPhase 2Apr 1, 2005
- NCT01035528CollaboratorPhase 4Apr 1, 2005
- NCT00177255CollaboratorPhase 2Apr 1, 2005
- NCT00113347CollaboratorPhase 1Apr 1, 2005
- NCT01640782CollaboratorPhase 3Feb 1, 2005
- NCT00121758CollaboratorPhase 2Sep 1, 2004
Details
- Founded
- Schiltigheim, FR Jan 1, 1999
- First NDA
- Apr 20, 2000
- Last known activity
- Jan 1, 2017
Designations held
- Priority review
- Accelerated approval
Notes
Aventis formed through merger of Rhône-Poulenc Rorer and Hoechst AG (headquarter in Strasburg, France)